Moxifloxacina Vioser (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacina Vioser, is a fluoroquinolone presented as an intravenous solution for intravenous use. It treats a range of serious bacterial infections in adult patients.

GNH USA supplies Moxifloxacina Vioser as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is indicated for several serious bacterial infections affecting the respiratory, sinus, skin, intra‑abdominal and bronchial systems.

- Community‑acquired bacterial pneumonia: effective treatment of infection caused by susceptible organisms. - Acute bacterial sinusitis: eradicates the causative pathogens and relieves sinus inflammation. - Complicated skin and skin‑structure infections: clears infection in deep or extensive skin lesions. - Complicated intra‑abdominal infections: targets mixed aerobic and anaerobic bacteria. - Acute bacterial exacerbations of chronic bronchitis: reduces bacterial load and improves lung function.

Adverse reactions may vary from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, occasionally leading to dehydration. - Headache: transient cranial discomfort. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: erythematous skin eruption. - Injection site reactions: pain, erythema, or swelling at the infusion site.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of ventricular arrhythmias. - Clostridioides difficile infection: severe colitis after antibiotic exposure. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: rare but potentially life‑threatening liver injury. - Seizures: especially in patients with pre‑existing CNS disorders.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic impairment: evaluate liver enzymes and adjust therapy if needed. - History of tendon disorders: avoid use due to risk of tendon rupture. - Concomitant QT‑prolonging drugs: monitor ECG and electrolytes. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: increased risk of cumulative toxicity. - Concurrent use with QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antibacterial activity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may affect drug stability. - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring. - Corticosteroids: increased likelihood of tendon injury.